Press Release: Carisma Therapeutics Reports First Quarter 2024 Financial Results and Recent Business Highlights

Dow Jones05-09
                                  --------------------  -------------------- 
Operating expenses: 
 Research and development                       17,462                16,641 
 General and administrative                      5,445                 9,574 
                                  --------------------  -------------------- 
   Total operating expenses                     22,907                26,215 
                                  --------------------  -------------------- 
   Operating loss                             (19,510)              (22,972) 
Change in fair value of 
 derivative liability                               --                  (84) 
Interest income (expense), net                     532               (1,477) 
                                  --------------------  -------------------- 
Pre-tax loss                                  (18,978)              (24,533) 
Income tax expense                                  --                 (109) 
                                  --------------------  -------------------- 
Net loss                            $         (18,978)    $         (24,642) 
                                  ====================  ==================== 
 
Share information: 
Net loss per share of common 
 stock, basic and diluted         $             (0.46)  $             (1.93) 
                                  ====================  ==================== 
Weighted-average shares of 
 common stock outstanding, basic 
 and diluted                                40,938,464            12,783,523 
                                  ====================  ==================== 
Comprehensive loss 
 Net loss                           $         (18,978)    $         (24,642) 
 Unrealized gain on marketable 
  securities                                        --                   177 
                                  --------------------  -------------------- 
Comprehensive loss                  $         (18,978)    $         (24,465) 
                                  ====================  ====================

View original content to download multimedia:https://www.prnewswire.com/news-releases/carisma-therapeutics-reports-first-quarter-2024-financial-results-and-recent-business-highlights-302140575.html

SOURCE Carisma Therapeutics Inc.

(END) Dow Jones Newswires

May 09, 2024 07:30 ET (11:30 GMT)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment